Use of letrozole in assisted reproduction: a systematic review and meta-analysis
Open accessThe DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Letrozole is the third-generation aromatase inhibitor (AI) most widely used in assisted reproduction. AIs induce ovulation by inhibiting estrogen production; the consequent hypoestrogenic state increases GnRH release and pituitary follicle-stimulating hormone (FSH) synthesis. METHODS: A systematic search of the literature was performed for both prospective and retrospective studies. Meta-analyses of randomized clinical trials (RCTs) were performed for three comparisons: letrozole versus clomiphene citrate (CC), letrozole + FSH versus FSH in intrauterine insemination (IUI) and letrozole + FSH versus FSH in IVF. In the absence of RCTs, non-randomized studies were pooled. RESULTS: Nine studies were included in the meta-analysis. Four RCTs compared the overall effect of letrozole with CC in patients with polycystic ovary syndrome. The pooled result was not significant for ovulatory cycles (OR = 1.17; 95% CI 0.66-2.09), or for pregnancy rate per cycle (OR = 1.47; 95% CI 0.73-2.96) or for pregnancy rate per patient (OR = 1.37; 95% CI 0.70-2.71). In three retrospective studies which compared L + FSH with FSH in ovarian stimulation for IUI, the pooled OR was 1.15 (95% CI 0.78-1.71). A final meta-analysis included one RCT and one cohort study that compared letrozole + gonadotrophin versus gonadotrophin alone: the pooled pregnancy rate per patient was not significantly different (OR = 1.40; 95% CI 0.67-2.91). CONCLUSIONS: Letrozole is as effective as other methods of ovulation induction. Further randomized-controlled studies are warranted to define more clearly the efficacy and safety of letrozole in human reproduction.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Androgens stimulate early stages of follicular growth in the primate ovary
Vendola, K. A., Zhou, J., Adesanya, O. O., Weil, S. J., & Bondy, C. A. (1998) · Journal of Clinical Investigation · doi:10.1172/jci2081 · Cited by 712 · cited 1×
“The androgens may also increase FSH receptors making women with PCOS exquisitely sensitive to an increase in FSH through exogenous administration of gonadotrophins, and hence the high risk of ovarian hyperstimulation syndrome and multiple ovulation (Vendola et al., 1998).”
BackgroundAndrogen and follicle stimulating hormone interactions in primate ovarian follicle development
Weil, S., Vendola, K., Zhou, J., & Bondy, C. A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.8.5929 · Cited by 592
Goswami, S. K. (2004) · Human Reproduction · doi:10.1093/humrep/deh359 · Cited by 372 · cited 2×
“Keywords: androgens; FSH; IVF”
BackgroundWeil, S. J., Vendola, K., Zhou, J., Adesanya, O. O., Wang, J., Okafor, J., & Bondy, C. A. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.7.4917 · Cited by 359 · cited 4×
“However, studies of ovarian follicular development in primates support a stimulatory role for androgens in early follicular growth (Weil et al., 1998).”
BackgroundInfluentialFisher, S. A., Reid, R. L., Van Vugt, D. A., & Casper, R. F. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(02)03241-7 · Cited by 347 · cited 1×
“Augmenting endogenous FSH with CC treatment is associated with a risk of ovarian hyperstimulation syndrome and multiple gestations (Fisher et al., 2002).”
BackgroundMechanism and inhibition of cytochrome P-450 aromatase
Cole, P. A., & Robinson, C. H. (1990) · Journal of Medicinal Chemistry · doi:10.1021/jm00173a001 · Cited by 319 · cited 1×
“In post-menopausal women, the main source of estrogens is the adipose tissue (Cole and Robinson, 1990).”
BackgroundGarcia, J., Jones, G. S., & Wentz, A. C. (1977) · Fertility and Sterility · doi:10.1016/s0015-0282(16)42670-1 · Cited by 233
A new era in ovulation induction
Holzer, H., Casper, R., & Tulandi, T. (2006) · Fertility and Sterility · doi:10.1016/j.fertnstert.2005.05.078 · Cited by 194 · cited 4×
“First-generation (aminoglutethimide) and second-generation (fadrozol and formestane) AIs are no longer used because of problems caused by their low potency, lack of specificity and side effects, especially with aminoglutethimide (Holzer et al., 2006).”
BackgroundInfluentialSonographic determination of a possible adverse effect of clomiphene citrate on endometrial growth
Gonen, Y., & Casper, R. F. (1990) · Human Reproduction · doi:10.1093/oxfordjournals.humrep.a137165 · Cited by 193
Pregnancy outcome after the use of an aromatase inhibitor for ovarian stimulation
Mitwally, M. F., Biljan, M. M., & Casper, R. F. (2005) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2004.08.013 · Cited by 186
A randomized trial of letrozole versus clomiphene citrate in women undergoing superovulation
Al-Fozan, H., Al-Khadouri, M., Tan, S. L., & Tulandi, T. (2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2004.04.070 · Cited by 174 · cited 2×
“Al-Fozan et al. (2004) compared the effects of the letrozole (7.”
BackgroundInfluentialHealey, S., Tan, S. L., Tulandi, T., & Biljan, M. M. (2003) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.03.001 · Cited by 132 · cited 3×
“In a retrospective analysis, Healey et al. (2003) compared FSH alone or a combination of FSH and letrozole 5 mg/day and also showed that women co-treated with letrozole developed more follicles .14 mm.”
BackgroundMethodPlourde, P. V., Reiter, E. O., Jou, H.-C., Desrochers, P. E., Rubin, S. D., Bercu, B. B., Diamond, F. B., Backeljauw, P. F., & Study, M. O. T. A. G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-0082 · Cited by 128 · cited 2×
“The experiment duration was insufficient to definitively evaluate t1/2 and AUC0–1; however, the interim parameters AUC0–last and Cmax, and Cmin and Tmax were all considered sufficient to meet the study objective and to confirm the published profile for anastrozole in post-menopausal women (Boeddinghaus and Dowsett, 20…”
ResultComparison of two aromatase inhibitors in women with clomiphene‐resistant polycystic ovary syndrome
Al‐Omari, W. R., Sulaiman, W. R., & Al‐Hadithi, N. (2004) · International Journal of Gynecology & Obstetrics · doi:10.1016/j.ijgo.2003.11.010 · Cited by 113
Young, S. L., Opsahl, M. S., & Fritz, M. A. (1999) · Fertility and Sterility · doi:10.1016/s0015-0282(98)00537-8 · Cited by 111 · cited 1×
“Unintended, adverse, antiestrogenic effects of CC on the quality and quantity of cervical mucus production or endometrial proliferation and maturation have been related to accumulation of zuC (Young et al., 1999).”
BackgroundAromatase inhibitors in ovulation induction
(2004) · Seminars in Reproductive Medicine · doi:10.1055/s-2004-823028 · Cited by 87
Letrozole: ovulation or superovulation?
Casper, R. F. (2003) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.05.004 · Cited by 64 · cited 8×
“Finally, nine studies were included with a total of 2573 women.”
BackgroundMethodInfluential
Cited by
Azziz, R., Carmina, E., Chen, Z., Dunaif, A., Laven, J. S. E., Legro, R. S., Lizneva, D., Natterson-Horowtiz, B., Teede, H. J., & Yildiz, B. O. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.57 · Cited by 2,005
Metadata
- Authors
- Requena, A., Herrero, J., Landeras, J., Navarro, E., Neyro, J. L., Salvador, C., Tur, R., Callejo, J., Checa, M. A., Farre, M., Espinos, J. J., Fabregues, F., Grana-Barcia, M., & Reproductive Endocrinology Interest Group of the Spanish Society of Fertility
- Venue
- Human Reproduction Update
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-09-29
- Volume
- 14
- Issue
- 6
- Pages
- 571-582
- ISSN
- 1355-4786 (ISSN-L)
- 1460-2369
- OpenAlex
- W2096067447
- Cited by
- 197
- References
- 17
- FWCI
- 1.52
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.